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Association of decreased calcium-sensing receptor expression Expression of vitamin D receptor (VDR) is known to
with proliferation of parathyroid cells in secondary hyperpara- be decreased in the parathyroid (PT) glands from the
thyroidism. early/predialysis stage of chronic renal failure [1]. TheBackground. The down-regulation of both calcium-sensing
expression of VDR negatively correlated with the prolif-receptor (CaSR) and vitamin D receptor (VDR) in parathyroid
(PT) glands of secondary hyperparathyroidism (HPT) caused erative activity of the hyperplastic PT glands from pa-
by chronic renal failure has been associated with PT hormone tients with secondary hyperparathyroidism (secondary
hypersecretion as well as PT hypergrowth. To clarify the pre- HPT) [2]. An active vitamin D metabolite, 1,25(OH)2D3,dominance of decreased expression of CaSR and VDR in the
which partially restores the VDR expression level, sup-high proliferative activity of PT glands, we examined the rela-
presses not only PT hormone (PTH) synthesis at thetionship between the expression of both receptors and prolifer-
ative activity in human PT glands. mRNA level but also PT cell proliferation through the
Methods. Serial sections of 56 PT glands, including 52 glands receptor [3–6]. An intermittent administration of high
from secondary HPT and 4 normal PT glands resected together
doses of 1,25(OH)2D3 can reduce the serum PTH levelwith thyroid carcinoma, were examined immunohistochemi-
as well as the volume of the PT gland in many casescally with specific antibodies against CaSR, VDR, and Ki67.
The Ki67-positive cell number was counted and expressed as of secondary HPT [7–9]. However, in some cases, this
the Ki67 score. The CaSR and VDR expressions were semi- 1,25(OH)2D3 pulse therapy cannot induce the appro-
quantitatively analyzed. priate PTH levels or must be discontinued as a result ofResults. The expressions of both CaSR and VDR were
side effects, which inevitably include hypercalcemia andmarkedly decreased in PT glands of secondary HPT, while
hyperphosphatemia. This suggests that alterations in thethe Ki67 score was significantly higher than it was in normal
controls. When hyperplastic glands were classified into two vitamin D–VDR axis might not be the only determinants
subgroups, with [N(1)] or without [N(2)] nodular formation, of the pathological growth of the PT glands in chronic
CaSR expression was significantly decreased in N(1), while
renal failure.VDR expression was not different. Multiple regression analy-
The calcium-sensing receptor (CaSR) plays a crucialses revealed that the decreased expression of CaSR could con-
tribute significantly to the high proliferative activity, even if role in the regulation of PTH secretion [10]. A loss of
VDR expression was taken into account. CaSR function leads to pathological states such as famil-
Conclusion. The decrease in CaSR expression is associated ial hypocalciuric hypercalcemia (FHH) and neonatal se-with the high proliferative activity of PT glands in secondary
vere hyperparathyroidism (NSHPT) with enlargementHPT, independently of the decreased VDR expression. These
of PT glands in severe cases [11–13]. CaSR knockoutfindings provide a new insight into the pathogenesis of PT
hyperplasia, which is refractory to vitamin D therapy in patients mice also had enlarged PT glands [14]. Moreover, in the
with severe secondary HPT. rat model of renal failure, CaSR agonists suppressed the
progression of secondary HPT as well as PT growth [15].
Recently, CaSR down-regulation has been demonstratedKey words: calcium-sensing receptor, vitamin D receptor, chronic renal
failure, proliferation, secondary hyperparathyroidism. in hyperplastic PT glands from secondary HPT, espe-
cially in nodular areas of hyperplasia, compared with that
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Table 1. Clinical characteristics and baseline data in all cases
SCa SP SCrGender Age ALP Intact PTH
Diagnosis Case F/M year IU/L pg/mLmg/dl
Secondary HPT 18 10/8 47.561.7 10.6760.22 6.3260.34 10.0560.56 18206847 17156216
Normal 4 4/0 54.066.4 9.0360.34 3.5860.24 0.6860.05 226639 2663
All data are mean 6 SE. Abbreviations are: F/M, female/male; SCa, serum calcium; SP, serum phosphorus; SCr, serum creatinine; ALP, alkaline phosphatase; PTH,
parathyroid hormone; HPT, hyperparathyroidism.
Duration of hemodialysis was 13.4 6 1.6 years in secondary HPT patients.
Serum Ca levels were corrected by serum albumin.
of CaSR is associated with the growth potency of PT kit; Nichols Institute Diagnostics, San Juan Capistrano,
CA, USA) [20].glands in patients with secondary HPT.
In the present study, we examined the relationship
Antibodiesbetween the proliferative activity and the expression lev-
The antihuman CaSR antibody, kindly provided byels of CaSR as well as VDR in order to clarify the pre-
Dr. K. Rogers (NPS Pharmaceuticals, Salt Lake City,dominance of decreased expression of CaSR and VDR in
UT, USA), was a mouse monoclonal antibody againstthe high proliferative activity of PT glands from patients
residues 214 to 235 (ADD) of the human CaSR extracel-diagnosed with severe secondary HPT who were under-
lular domain, as previously described [21]. A rat mono-going hemodialysis.
clonal antihuman VDR antibody (9A7r.E10.E4) was
purchased from NeoMarkers (Fremont, CA, USA), and
METHODS a rabbit affinity-purified antihuman Ki67 antigen was
purchased from Dako (Glostrup, Denmark).Subjects
Fifty-six PT gland tissue samples were obtained during Immunohistochemistry
parathyroidectomy, including 52 glands from 18 patients
Immunohistochemical staining was performed usingwith severe secondary HPT who were undergoing chronic
formalin-fixed and paraffin-embedded sections. Sectionshemodialysis. The duration of hemodialysis treatment in
were deparaffinized in xylene and rehydrated throughsecondary HPT patients was 13.4 6 1.6 (mean 6 SE)
an ethanol series. Then endogenous peroxidase was inac-years. Four normal PT glands resected together with
tivated with 0.3% H2O2 in methanol for 20 minutes atthyroid carcinoma from four patients whose renal func-
room temperature. After washing twice with phosphate-tion was normal were employed as the controls. Clinical
buffered saline (PBS), sections were processed in dis-
features and baseline data of these patients are shown
tilled H2O for 10 minutes using a medical microwavein Table 1. All patients with secondary HPT were treated (MI-77; Higashiya, Tokyo, Japan) at 400 W for VDR
with active vitamin D: alphacalcidol [1a(OH)D3, 0.25 or and Ki67 staining [22]. After blocking with 1.5% nonfat
0.5 mg daily, 9 patients] or intermittent high doses of dry milk in PBS for 10 minutes, sections were incubated
calcitriol [1,25(OH)2D3, 4 or 8 mg weekly] by oral admin- with primary antibody overnight at 48C. For the incuba-
istration (the other patients) [18]. As their serum calcium tions, ADD was diluted 1:1200 in PBS containing 1%
(Ca) and phosphorus (P) levels were difficult to be con- nonimmunized mouse serum); 9A7r was diluted 1:50,
trolled as a result of side effects (hypercalcemia and and anti-Ki67 antigen was diluted 1:100. After washing
hyperphosphatemia), total parathyroidectomy was re- thoroughly with PBS, samples were incubated with a
quired in all patients to improve their bone metabolism biotinylated-linking antibody (containing anti-rabbit and
and calcium homeostasis. All samples from the second- anti-mouse immunoglobulins) and peroxidase-labeled
ary HPT cases were histologically diagnosed as hyperpla- streptavidin using an LSAB2 kit (Dako Corp., Carpin-
sia. Each patient gave informed consent to this study. teria, CA, USA) for 30 minutes, respectively. Final de-
velopment was carried out with 3,3-diaminobenzidine
Assay methods (DAB) containing 0.1% H2O2 in PBS for 10 minutes
The preoperative concentrations of serum levels of [23]. Slides were counterstained with hematoxylin for 30
Ca, P, creatinine (Cr), albumin, and alkaline phosphatase seconds only for CaSR staining. For staining of VDR
(ALP) were assayed by standard methods. The normal and Ki67-antigen, Ni21 and Co21 were added to the DAB
range of serum ALP level was from 100 to 303 IU/L. The solution to final concentrations of 0.3%, respectively.
corrected serum Ca level was calculated using Payne’s Negative controls using preimmune mouse serum were
formula [19]. The serum intact PTH level was measured prepared. We performed stains strictly in the same way
and obtained a good reproducibility of each stain beforeby immunoradiometric assay (Allegro Intact PTH-RIA
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starting this study. To standardize the intensity of stain positive cells were found in the nodular area than that
in each experiment, we took care especially for the final in the diffuse area (Fig. 2b). On the other hand, no
incubation time and put standard slides with positive decrease in VDR expression was observed in the nodular
and negative controls. Then we investigated the quantita- area (Fig. 2c). In case 2 with diffuse hyperplasia, CaSR
tion of these signals. expression was markedly decreased in a cluster of PT
cells without capsule formation (Fig. 2d). In these cells,
Quantification of immunohistochemical signals Ki67-positive proliferative activity was frequently ob-
Each slide was observed under a light microscope, and served (Fig. 2e), while VDR expression was not de-
at least six areas were randomly selected on the serial creased, compared with the surrounding cells (Fig. 2f).
slide of hematoxylin and eosin stain without knowledge Thus, we further analyzed the relationships between pro-
of the other immunohistochemical signals. The immuno- liferative activity and the expressions of CaSR as well
reactivities for CaSR, VDR, and Ki67 antigen were eval- as VDR in secondary hyperplastic PT glands with a sta-
uated in each area marked by one observer. The CaSR tistical technique.
and VDR signals were scored according to the percent- When all specimens were analyzed according to the
age of positive cells using the following grading criteria: criteria of Fukuda et al, the Ki67 score was higher (P ,
grade 3, more than 75%; grade 2, 50 to 75%; grade 1, 0.01), and the expression levels of both CaSR and VDR
25 to 50%; and grade 0, below 25% (Fig. 1). The number were significantly lower (P , 0.01) in nodular areas than
of Ki67-positive cells in each area, counted at a magnifi- in diffuse areas (data not shown) [24]. Although these
cation of 3200, was designated as the Ki67 score. This findings were compatible with those described previously
analysis was performed by three independent observers [17, 24], information on the diffuse areas in the glands
(the coefficients of variation were 3.8, 2.7, and 3.3%). with nodular formation was excluded using this criteria.
After taking an average of the scores for the six areas, Therefore, to evaluate PT function as a whole gland,
CaSR and VDR immunoreactive scores as well as the hyperplastic PT glands were subdivided into two groups,
Ki67 score were given to each gland. Using these scores, PT glands with and without nodular formation, N(1)
we performed statistical analyses to investigate the asso- and N(2), respectively. Among 52 hyperplastic glands,
ciation between PT cell proliferative activity and CaSR single or multiple nodular formation was observed in
as well as VDR expression. 40 glands, N(1), and a diffuse hyperplastic pattern was
observed in 12 glands, N(2).Statistical analysis
A comparison of scores for Ki67, CaSR, and VDR
All data were expressed as mean 6 SE. One-way anal- immunoreactivity in the two subtypes of hyperplasia is
ysis of variance (ANOVA), multiple comparison tests, shown in Figure 3. The Ki67 score was significantly
an unpaired t-test, and a single- or multiple-regression higher in the N(1) group than in the N(2) group. CaSR
analysis were performed using a program for the Macin- expression was decreased in the N(1) group compared
tosh computer (Stat View 4.5; Abacus Concepts, Inc., with the N(2) group. As for VDR expression, there
Berkeley, CA, USA). Statistical significance was consid- were no statistical differences between the two groups,
ered at P values of less than 0.05. although a similar tendency was found.
Single regression analyses were performed between
the Ki67 score and the CaSR as well as VDR scores inRESULTS
hyperplastic glands of secondary HPT. The Ki67 scoreThe immunohistochemical findings of PT in each
had negative and significant correlations with both thegroup are shown in Table 2. As expected, Ki67-positive
CaSR score (r 5 0.457, P 5 0.0007) and the VDR scorecells were found more in hyperplastic PT glands than in
(r 5 0.310, P 5 0.0253).normal ones. On the other hand, the expression of VDR,
Since the VDR score had a good correlation with thewhich occurs mostly in the nucleus of PT cells, was sig-
CaSR score (R 5 0.653, P , 0.0001), multiple-regressionnificantly decreased in hyperplastic PT glands, as re-
analyses were performed to determine the predominanceported previously by others [1, 24]. Interestingly, the
of decreased expression of CaSR and VDR in the highCaSR staining, which was mostly observed at the cell–cell
proliferative activity. As shown in Table 3, the Ki67 scoreborder of the cells, also showed weaker reactivity with
was negatively and significantly correlated with CaSRthe antibody specific for CaSR in the hyperplastic glands.
expression, even if VDR expression was taken into ac-Careful observation of serial sections (Fig. 2) suggested
count. In contrast, the correlation between the Ki67that the CaSR signal intensities were independent of the
score and VDR expression was not significant, if CaSRVDR expression levels in Ki67-positive hyperplastic PT
expression was taken into account. These data clearlyglands. For example, in case 1 with nodular hyperplasia,
indicate that the decrease in CaSR expression is associ-CaSR expression was decreased in the nodular area (in-
side a capsule; Fig. 2a). In a serial section, more Ki67- ated with the higher proliferative activity of PT glands
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Fig. 1. Semiquantification based on the stain
intensity of calcium-sensing receptor (CaSR)
and vitamin D receptor (VDR). CaSR is ex-
pressed mostly at the cell–cell border of the
PT cells, and VDR is expressed mostly in the
nucleus. Each area randomly selected was
scored as follows: grade 3, CaSR (a) and VDR
(e); grade 2 (b) and ( f ); grade 1 (c) and (g); and
grade 0 (d) and (h), respectively, according to
the criteria described in the Methods section.
Fig. 2. CaSR, VDR, and Ki67 immunohisto-
chemical staining in representative cases. CaSR
expression was markedly decreased in nodular
areas (inside a capsule; a) as well as in a cluster
of parathyroid (PT) cells without a capsule
(inside arrows; d). Notably, in serial sections
there were many Ki67-positive cells (b and e),
although VDR expression did not decrease (c
and f ) in these areas.
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Table 2. Immunohistochemical findings in relation to subtypes of the parathyroid glands
Histological Ki67 score
diagnosis Total glands Weight g /field 3 200 CaSR score VDR score
Hyperplasia 52 1.2760.17 26.6662.67a 1.1960.08a 1.1560.06a
Normal 4 — 0.4560.21 2.7560.05 2.8060.08
Data are mean 6 SE. Abbreviations are: CaSR, calcium-sensing receptor; VDR, vitamin D receptor.
aP vs. with normal
Fig. 3. Comparison of Ki67, CaSR, and VDR
scores in subtypes of the parathyroid (PT)
glands with nodular formation [N(1)] and
without nodular formation [N(2)]. *P , 0.01;
**P , 0.05 compared with N(2).
in secondary HPT and that this association is indepen- In our study, single regression analyses displayed a
dent of the decreased VDR expression. significant correlation between the Ki67 score and CaSR
as well as VDR expression, but the strength of the corre-
lation was higher with CaSR than with VDR. Moreover,DISCUSSION
in the multiple-regression analysis, the negative correla-
In the present study, decreased expression of CaSR tion was still significant, even when VDR expression was
as well as VDR and increased Ki67-positive cells were taken into account. Taken together, these results indicate
observed in PT glands from patients with secondary HPT that the decreased expression of CaSR could be associ-
when compared with normal controls, confirming previ- ated with the proliferative activity of PT cells in a manner
ous observations [25, 26]. The Ki67 nuclear antigen, a independent of VDR. Alternatively, the significant cor-
345 to 395 kD nonhistone protein, is expressed in cells relation between the decrease of VDR expression and
in the G1, S, G2, and M stages, but not in the G0 stage the proliferative activity shown in the single-regression
[27]. Ki67 antigen, as well as proliferating cell nuclear
analyses might be caused simply by the decreased level
antigen (PCNA), a 36 kD nonhistone nuclear polypep-
of CaSR. Indeed, there is supportive evidence that CaSRtide, are present in proliferating cells. A strong correla-
expression is regulated by active vitamin D3, althoughtion between PCNA and Ki67 counts has been reported
some results conflict with this conclusion [29, 30]. Since[28]. Both the PCNA and Ki67 counts are useful as
the severity of the secondary HPT might affect the rela-indicators of the proliferative potential as well as the
tionships between the proliferative activity and the ex-prognosis of some kinds of cancer. In hyperplastic glands,
pression of CaSR as well as VDR, further study is re-the PT glands in the N(1) group showed higher prolifer-
quired to elucidate the mechanism by which vitamin Dative activity than those in the N(2) group. CaSR but
regulates the expression level of CaSR in the PT.not VDR expression was significantly decreased in N(1)
Although a direct effect of CaSR on PT growth couldcompared with N(2). The present findings suggest that
not be proved in this study, our multiple-regression anal-CaSR down-regulation is more closely associated with
yses indicate that CaSR could alter the regulations ofhigh proliferative activity than VDR down-regulation.
PTH secretion as well as cell proliferation in humanOn the other hand, as for VDR expression, Fukuda et
pathological PT glands, probably irrespective of theal reported that VDR staining was decreased in nodular
1,25(OH)2D3–VDR axis. It remains to be determinedtype hyperplasia compared with the diffuse type [24].
whether CaSR is directly or indirectly involved in theOur data gave similar results when we used their criteria
regulation of PT growth through its own signaling path-in which the expression was assessed only within nodular
way or mediated by unknown factors other than theareas in nodular type hyperplasia. The discrepancy be-
vitamin D–VDR axis. In PT cells, PTH synthesis andtween our results and those of Fukuda et al concerning
secretion, and probably PT cell proliferation, have beenVDR expression could be explained mainly by the meth-
odological differences of analysis. inhibited by high concentrations of extracellular Ca in
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Table 3. Multiple regression analysis of Ki67-positive cell REFERENCES
numbers against CaSR and VDR expression in secondary
hyperplastic glands 1. Korkor AB: Reduced binding of [3H]1,25-dihydroxyvitamin D3 in
the parathyroid glands of patients with renal failure. N Engl J Med
Dependent Independent Parameter estimate 316:1573–1577, 1987
variable variables (SE) P value 2. Koike T, Fukuda N, Fukagawa M, Ohta K, Kurokawa K: Corre-
lation of enhanced cell proliferation with decreased density ofKi67 VDR 20.99967.926 0.9002
vitamin D receptor in parathyroid hyperplasia in chronic dialysisCaSR 214.54865.512 0.0111
patients. Nephrology 3:279–284, 1997
Abbreviations are in Table 2. 3. Silver J, Russell J, Sherwood LM: Regulation by vitamin D
metabolites of messenger RNA for pre-proparathyroid hormone
in isolated bovine parathyroid cells. Proc Natl Acad Sci USA
82:4270–4273, 1985
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monocyte-macrophage cells, which express endogenous proto-oncogene expression in primary cultures of bovine parathy-
roid cells. Endocrinology 125:935–941, 1989CaSR [31–34], and fibroblasts transfected with functional
6. Szabo A, Merke J, Beier E, Mall G, Ritz E: 1,25(OH)2 vitaminCaSR [35]. Increases of c-Src kinase and mitogen-acti- D3 inhibits parathyroid cell proliferation in experimental uremia.
vated protein kinase activity have also been demon- Kidney Int 35:1049–1056, 1989
7. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martinstrated to be involved in this mechanism [36]. Thus, a
KJ: Marked suppression of secondary hyperparathyroidism by in-
complete understanding of the intracellular signaling in travenous administration of 1,25-dihydroxy-cholecalciferol in ure-
mic patients. J Clin Invest 74:2136–2143, 1984CaSR-induced PT cell growth inhibition requires further
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polsky E: Parathyroid hormone suppression by intravenous 1,25-
High-dose 1,25(OH)2D3 pulse therapy is effective in dihydroxyvitamin D: A role for increased sensitivity to calcium. J
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10. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R,refractory to this therapy. Based on this clinical evidence, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC: Cloning
and characterization of an extracellular Ca21-sensing receptor fromwe sought to determine whether the expression level of
bovine parathyroid. Nature 366:575–580, 1993CaSR might contribute to PT growth with enlarged PT
11. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ,
glands from severe secondary HPT patients. Our statisti- Steinmann B, Levi T, Seidman CE, Seidman JG: Mutations in the
human Ca21-sensing receptor gene cause familial hypocalciuriccal analyses demonstrate that the decrease in CaSR ex-
hypercalcemia and neonatal severe hyperparathyroidism. Cellpression is associated with the higher proliferative activ- 75:1297–1303, 1993
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